Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Springer

Journal: Annals of Hematology
Publisher: Springer Berlin / Heidelberg
ISSN: 0939-5555 (Print) 1432-0584 (Online)
Issue: Volume 48, Number 4 / April, 1984
Category: Short Communications
DOI: 10.1007/BF00319816
Pages: 239-242
Subject Collection: Medicine
SpringerLink Date: Friday, December 03, 2004

H. J. Weh1, R. Zschaber1 and D. K. Hossfeld1
(1) Department of Oncology and Hematology, University of Hamburg, Martinistr. 52, D-2000 Hamburg 20, Federal Republic of Germany

Received: 28 October 1983 Accepted: 25 November 1983
Summary Ten AML- and two MDS-patients in whom conventional chemotherapy was contraindicated or ineffective were treated with low dose ARA-C, 10 mg/m2 per 12hs.c. for 2–4 weeks. Seven patients obtained a complete and two a partial remission. Our findings suggest that low dose ARA-C may act both by induction of differentiation and/or inhibition of proliferation.

© Springer

This article may be viewed in its entirety by purchase at the website.